The FDA has reclassified radiological computer-assisted detection (CAD) and diagnosis (CADx) software from class III (highest risk) to class II (special controls).
Key Details
- 1The FDA finalized the order on June 13, moving CAD/CADx software used in radiology to class II regulation.
- 2Devices affected include software aiding detection and diagnosis on medical images like CT, MRI, and X-ray.
- 3Special controls now apply, such as design verification, validation, and clear labeling requirements.
- 4This change lowers the regulatory burden, enabling access via the 510(k) process instead of De Novo or PMA routes.
- 5Reclassification intends to maintain safety and effectiveness while enhancing patient and industry access to innovative tools.
Why It Matters
This regulatory change will significantly streamline the approval process for imaging AI developers, reducing time-to-market and promoting innovation. For radiologists, it could lead to faster clinical adoption of advanced CAD tools, with maintained safety standards.
Source
AuntMinnie
Related News
•Radiology Business
Better Medicine Raises $7M to Expand Radiology AI for Kidney Lesions
Estonia-based Better Medicine raises nearly $7 million to expand its radiology AI solution and enter the U.S. market.
•AuntMinnie
ChatGPT-4 Turbo Powers Postdeployment Monitoring of ICH Detection AI
Researchers found ChatGPT-4 Turbo could efficiently monitor the performance of Aidoc's ICH detection AI across real-world radiology practices.
•Radiology Business
Heartflow Raises $364M in Highly Subscribed Public Offering
Cardiac imaging AI company Heartflow raised $364 million from an upsized public stock offering, far exceeding expectations.